Sugi Predict

Sugi Predict / Compounds / SCHEMBL3317660

SCHEMBL3317660

SCHEMBL3317660

O=C(CCCl)Nc1ccc(F)cc1

nearest known ligand 0.68

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HDAC3 O15379 2/20 0.62
▸ HDAC1 Q13547 2/20 0.62
▸ HDAC2 Q92769 2/20 0.62
▸ HDAC6 Q9UBN7 2/20 0.62
▸ TP53 P04637 2/20 0.59
▸ GAA P10253 3/20 0.59
▸ ALDH1A1 P00352 4/20 0.56
▸ KMT2A Q03164 4/20 0.55
▸ MEN1 O00255 2/20 0.55
▸ MAPT P10636 1/20 0.55
▸ ATM Q13315 1/20 0.53
▸ KDM4E B2RXH2 1/20 0.51
▸ THRB P10828 1/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ LMNA P02545 1/20 0.51
▸ RXFP1 Q9HBX9 1/20 0.51
▸ RAB9A P51151 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8075597 0.85 TP53 (0.72) HDAC3HDAC1HDAC2HDAC6TP53
SCHEMBL1193345 0.84 NPC1 (0.63) HDAC3HDAC1HDAC2HDAC6TP53
SCHEMBL1325326 0.82 ALDH1A1 (0.66) TP53GAAALDH1A1KMT2AMEN1
SCHEMBL2205077 0.82 CYP1A1 (0.67) TP53GAAALDH1A1KMT2AMEN1
SCHEMBL9386081 0.82 HDAC3 (0.64) HDAC3HDAC1HDAC2HDAC6TP53
SCHEMBL14816847 0.82 HDAC3 (0.64) HDAC3HDAC1HDAC2HDAC6TP53
SCHEMBL1753925 0.81 GAA (0.70) HDAC3HDAC1HDAC2HDAC6TP53
SCHEMBL14537631 0.81 HDAC3 (0.62) HDAC3HDAC1HDAC2HDAC6TP53
SCHEMBL7095470 0.81 CYP1A1 (0.70) HDAC3HDAC1HDAC2HDAC6TP53
SCHEMBL7095442 0.81 HDAC3 (0.62) HDAC3HDAC1HDAC2HDAC6TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3416633-B1 TETRAHYDROQUINOLINE SUBSTITUTED HYDROXAMIC ACIDS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS UNIV ILLINOIS (US) 2025-07-23 — — EP disclosed
EP-3998268-B1 COMPOUND FOR INHIBITING EGFR KINASE AND PREPARATION METHOD AND USE THEREOF WIGEN BIOMEDICINE TECH SHANGHAI CO LTD (CN) 2024-12-18 — — EP disclosed
CN-114026090-B Compound for inhibiting EGFR kinase and preparation method and application thereof 微境生物医药科技(上海)有限公司 2023-01-06 — — CN disclosed
EP-3998268-A1 COMPOUND FOR INHIBITING EGFR KINASE AND PREPARATION METHOD AND USE THEREOF Wigen Biomedicine Technology (Shanghai) Co., Ltd. (CN) 2022-05-18 — — EP disclosed
CN-114026090-A Compound for inhibiting EGFR kinase and preparation method and application thereof 微境生物医药科技(上海)有限公司 2022-02-08 — — CN disclosed
US-20210230161-A1 COMPOUNDS FOR INHIBITING EGFR KINASE, PREPARATION METHODS AND USES THEREOF Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) 2021-07-29 — — US disclosed
WO-2021000912-A1 COMPOUND FOR INHIBITING EGFR KINASE AND PREPARATION METHOD AND USE THEREOF 微境生物医药科技(上海)有限公司 2021-01-07 — — WO disclosed
CN-112174961-A Compound for inhibiting EGFR kinase and preparation method and application thereof 微境生物医药科技(上海)有限公司 2021-01-05 — — CN disclosed
US-10456394-B2 Tetrahydroquinoline substituted hydroxamic acids as selective histone deacetylase 6 inhibitors THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2019-10-29 — — US disclosed
US-10456394-B2 Tetrahydroquinoline substituted hydroxamic acids as selective histone deacetylase 6 inhibitors THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2019-10-29 — — US disclosed
EP-1260512-B1 NOVEL CYCLIC AMIDE DERIVATIVES MITSUBISHI PHARMA CORP (JP) 2007-07-04 — — EP disclosed
US-7166617-B2 Cyclic amide derivatives MITSUBISHI PHARMA CORPORATION (JP) 2007-01-23 — — US disclosed
US-20030212094-A1 Novel cyclic amide derivatives MITSUBISHI PHARMA CORPORATION (JP) 2003-11-13 — — US disclosed
CN-1426405-A Novel cyclic amide derivative MITSUBISHI PHARMACEUTICALS INC (JP) 2003-06-25 — — CN disclosed
EP-1260512-A1 NOVEL CYCLIC AMIDE DERIVATIVES Mitsubishi Pharma Corporation (JP) 2002-11-27 — — EP disclosed
EP-0852142-A1 Diamines in the treatment of arrhythmia SMITHKLINE BEECHAM LABORATOIRES PHARMACEUTIQUES (FR) 1998-07-08 — — EP disclosed
EP-0639973-A1 DIAMINES IN THE TREATMENT OF ARRHYTHMIA SMITHKLINE BEECHAM LABORATOIRES PHARMACEUTIQUES (FR) 1995-03-01 — — EP disclosed
WO-1993023024-A1 DIAMINES IN THE TREATMENT OF ARRHYTHMIA SMITHKLINE BEECHAM LABORATOIRES PHARMACEUTIQUES (FR) 1993-11-25 — — WO disclosed
EP-0162776-B1 HETEROCYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS USEFUL AS ALDOSE REDUCTASE INHIBITORS CONTAINING THEM LABORATOIRES UPSA (FR) 1989-04-19 — — EP disclosed
US-4755509-A Heterocyclic aldose reductase inhibitors and methods of using them Carbipem (FR) 1988-07-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210230161-A1 COMPOUNDS FOR INHIBITING EGFR KINASE, PREPARATION METHODS AND USES THEREOF EGFR, ERBB2, ERBB4 HDAC3 2873/4885HDAC1 2639/4885HDAC2 3316/4885
US-20030212094-A1 Novel cyclic amide derivatives SIGMAR1, OPRM1, OPRD1 HDAC3 369/4885HDAC1 455/4885HDAC2 882/4885
US-10456394-B2 Tetrahydroquinoline substituted hydroxamic acids as selective histone deacetylase 6 inhibitors HDAC1, HDAC5, HDAC7 HDAC3 9/4885HDAC1 1/4885HDAC2 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.